You just read:

Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200

News provided by

Protagonist Therapeutics, Inc.

Nov 06, 2018, 07:00 ET